Роль Helicobacter pylori в развитии метаболических и сердечно-сосудистых заболеваний

Инфекция Helicobacter pylori (H. pylori) является одной из наиболее распространенных в мире. Инфицированность населения земного шара превышает 50% и особенно высока в странах с низким социально-экономическим уровнем развития. H. pylori способна вызывать гастродуоденальные и экстрагастродуоденальные заболевания, в частности такие метаболические нарушения, как ожирение, сахарный диабет и неалкогольная жировая болезнь печени. Недавние эпидемиологические и клинические исследования также показали, что длительная персистенция H. pylori связана с развитием и прогрессированием атеросклероза и как следствие - возникновением сердечно-сосудистых заболеваний. Однако связь между ними неоднозначна и в литературе нет убедительных доказательств этой корреляции. Отсутствие консенсуса может быть связано с различиями в диагностике H. pylori и вариабельностью генотипов инфекции. Учитывая высокую распространенность H. pylori и значительную частоту метаболических и сердечно-сосудистых заболеваний, подтверждение связи между ними может иметь большое эпидемиологическое, профилактическое и клиническое значение.

1. Santos M.L.C., de Brito B. B., da Silva F. A.F., Sampaio M. M. et al. Helicobacter pylori infection: Beyond gastric manifestations. World J Gastroenterol. 2020; 26(28): 4076-4093. doi: 10.3748/wjg.v26.i28.4076.

2. Rogha M., Nikvarz M., Pourmoghaddas Z., Shirneshan K. et al. Is Helicobacter pylori infection a risk factor for coronary heart disease? ARYA Atheroscler. 2012 Spring;8(1):5-8. PMID: 23056092; PMCID: PMC3448393.

3. Дядык А. И., Куглер Т. Е. Кардиоваскулярные, ренальные и нейропсихические побочные эффекты эрадикационной терапии Helicobacter pylori. Лечащий врач; 2017. 8: 32-35.

4. Pellicano R., Ianiro G., Fagoonee S., Settanni C. R., et al. Review: Extragastric diseases and Helicobacter pylori. Helicobacter. 2020; 25 (Suppl. 1): e12741. doi: 10.1111/hel.12741.

5. Gravina A.G., Zagari R. M., De Musis C., Romano L., et al. Helicobacter pylori and extragastric diseases: A review. World J Gastroenterol. 2018; 24(29): 3204-3221 doi: 10.3748/wjg.v24.i29.3204.

6. Mansori K., Moradi Y., Naderpour S., et al. Helicobacter pylori infection as a risk factor for diabetes: a meta-analysis of case-control studies. BMC Gastroenterology. 2020; 77: 1-14. doi: 10.1186/s12876-020-01223-0.

7. Cuomo P., Papaianni M., Sansone C., Iannelli A. et al. An In Vitro Model to Investigate the Role of Helicobacter pylori in Type 2 Diabetes, Obesity, Alzheimer’s Disease and Cardiometabolic Disease. Int J Mol Sci. 2020; 21(21): 8369. doi: 10.3390/ijms21218369.

8. Mladenova I., Durazzo M. Transmission of Helicobacter pylori. Minerva Gastroenterol Dietol. 2018 Sep;64(3):251-254. doi: 10.23736/S1121-421X.18.02480-7.

9. Reshetnyak V.I., Burmistrov A. I., Maev I. V. Helicobacter pylori: Commensal, symbiont or pathogen? World J Gastroenterol. 2021; 27(7): 545-560. doi:10.3748/wjg.v27.i7.545.

10. Censini S., Stein M., Covacci A. Cellular responses induced after contact with Helicobacter pylori. Curr Opin Microbiol. 2001 Feb;4(1):41-6. doi: 10.1016/s1369-5274(00)00162-4.

11. El-Omar E.M., Carrington M., Chow W. H., McColl K. E., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000 Mar 23;404(6776):398-402. doi: 10.1038/35006081.

12. Успенский Ю. П., Барышникова Н. В. Инфекция Helicobacter pylori и метаболические нарушения: есть ли связь? Экспериментальная и клиническая гастроэнтерология. 2017; 143 (7): 107-114.

13. Маев И. В., Бакулин И. Г., Курилович С. А., Бакулина Н. В. и соавт. Helicobacter pylori и экстрагастродуоденальные заболевания: доказанные факты и предположения. Доказательная гастроэнтерология. 2018; 3: 45-58. doi: 10.17116/dokgastro2018703145.

14. Erol A., Atılgan H., Yavaşoğlu I. The prevalence of Helicobacter pylori in obese subjects. European Journal of Internal Medicine. 2009 Nov;20(7):695-7. doi: 10.1016/j.ejim.2009.07.013.

15. Lender N., Tally N. J., Enck P., Haag S., et al. Review article: Associations between Helicobacter pylori and obesity - an ecological study. Alimentary Pharmacology & Therapeutics. 2014 Jul;40(1):24-31. doi: 10.1111/apt.12790.

16. Wawro N., Amann U., Butt J., et al. Helicobacter pylori seropositivity: prevalence, associations, and the impact on incident metabolic diseases/risk factors in the population-based KORA Study. Front Public Health. 2019 Apr 24;7:96. doi: 10.3389/fpubh.2019.00096.

17. Lim S.H., Kim N., Kwon J. W., et al. Positive association between Helicobacter pylori infection and metabolic syndrome in a Korean population: a Multicenter Nationwide Study. Dig Dis Sci. 2019 Aug;64(8):2219-2230. doi: 10.1007/s10620-019-05544-3.

18. Yu Y., Cai J., Song Z., Wang J., et al. Association of Helicobacter pylori infection with metabolic syndrome in aged Chinese females. Exp Ther Med. 2019 Jun;17(6):4403-4408. doi: 10.3892/etm.2019.7509.

19. Xu X., Li W., Qin L., Yang W., Yu G., Wei Q. Relationship between Helicobacter pylori infection and obesity in Chinese adults: a systematic review with meta-analysis. PLoS One. 2019 Sep 11;14(9): e0221076. doi: 10.1371/journal.pone.0221076.

20. Liu R., Liu Q., He Y., Shi W., et al. Association between Helicobacter pylori infection and nonalcoholic fatty liver: A meta-analysis. Medicine (Baltimore). 2019 Nov;98(44): e17781. doi: 10.1097/MD.0000000000017781.

21. Герман С. В., Бобровницкий И. П. Инфекция Helicobacter pylori и гепатобилиарная патология. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(4):15-22. doi: 10.22416/1382-4376-2018-28-4-15-22.

22. Лазебник Л. Б., Тарасова Л. В., Комарова Е. А., Бусалаева Е. И. Влияние инфекции Helicobacter pylori на течение неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2019;172(12): 90-94. DOI: 10.31146/1682-8658-ecg-172-12-90-94.

23. Сарсенбаева А. С., Уфимцев К. А., Домрачева Е. В. Инфекция Helicobacter pylori и жировая инфильтрация печени. Экспериментальная и клиническая гастроэнтерология. 2020;178(6): 146-153. DOI: 10.31146/1682-8658-ecg-178-6-146-153.

24. Mantovani A., Turino T., Altomari A., et al. Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: an updated meta-analysis. Metabolism. 2019 Jul;96:56-65. doi: 10.1016/j.metabol.2019.04.012.

25. Zhou B.G., Yang H. J., Xu W., Wang K., et al. Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: a systematic review and meta-analysis of observational studies. Helicobacter. 2019 Jun;24(3): e12576. doi: 10.1111/hel.12576.

26. Ning L., Liu R., Lou X., et al. Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: a systemic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019 Jul;31(7):735-742. doi: 10.1097/MEG.0000000000001398.

27. Abo-Amer Y.E., Sabal A., Ahmed R., et al. Relationship between Helicobacter pylori infection and nonalcoholic fatty liver disease (NAFLD) in a developing country: a cross-sectional study. Diabetes Metab Syndr Obes. 2020 Mar 2;13:619-625. doi: 10.2147/DMSO.S237866.

28. Abdel-Razik A., Mousa N., Elhelaly R., et al. Helicobacter pylori as an initiating factor of complications in patients with cirrhosis: a single-center observational study. Front Med (Lausanne). 2020 Mar 24;7:96. doi: 10.3389/fmed.2020.00096.

29. Pellicano R., Ménard A., Rizzetto M., Mégraud F. Helicobacter species and liver diseases: association or causation? Lancet Infect Dis. 2008 Apr;8(4):254-60. doi: 10.1016/S1473-3099(08)70066-5.

30. Shaw J.E., Sicree R. A., Zimmet P. Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010 Jan;87(1):4-14. doi: 10.1016/j.diabres.2009.10.007.

31. Chen Y., Blaser M. J. Association between gastric Helicobacter pylori colonization and glycated hemoglobin levels. J. Infect. Dis. 2012; 205:1195-1202. doi: 10.1093/infdis/jis106.

32. Gunji T., Matsuhashi N., Sato H., Fujibayashi K., et al. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese population. Helicobacter. 2009; 14:144-150. doi: 10.1111/j.1523-5378.2009.00705.x.

33. Jeon C.Y., Haan M. N., Cheng C., Clayton E. R., et al. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care. 2012; 35:520-525. doi: 10.2337/dc11-1043.

34. Wang F., Fu Y., Lv Z. Association of Helicobacter pylori infection with diabetic complications: A meta-analysis. Endocr. Res. 2014; 39:7-12. doi: 10.3109/07435800.2013.794426.

35. Kim T.J., Lee H., Kang M., Kim J. E., et al. Helicobacter pylori is associated with dyslipidemia but not with other risk factors of cardiovascular disease. Sci. Rep. 2016; 6:38015. doi: 10.1038/srep38015.

36. Wada Y., Hamamoto Y., Kawasaki Y., Honjo S., et al. The eradication of Helicobacter pylori does not affect glycemic control in japanese subjects with type 2 diabetes. Jpn. Clin. Med. 2013; 4:41-43. doi: 10.4137/JCM.S10828.

37. Chen J., Xing Y., Zhao L., Ma H. The association between Helicobacter pylori infection and glycated hemoglobin A in diabetes: a meta-analysis. J Diabetes Res. 2019; 2019:3705264.

38. Li J.Z., Li J. Y., Wu T. F., et al. Helicobacter pylori infection is associated with type 2 diabetes, not type 1 diabetes: an updated meta-analysis. Gastroenterol Res Pract. 2017;2017:5715403. doi: 10.1155/2017/5715403.

39. Wang F, Liu J, Lv Z. Association of Helicobacter pylori infection with diabetes mellitus and diabetic nephropathy: a meta-analysis of 39 studies involving more than 20,000 participants. Scand J Infect Dis. 2013 Dec;45(12):930-8. doi: 10.3109/00365548.2013.844351.

40. Zhou X., Zhang C., Wu J., Zhang G. Association between Helicobacter pylori infection and diabetes mellitus: a meta-analysis of observational studies. Diabetes Res Clin Pract. 2013 Feb;99(2):200-8. doi: 10.1016/j.diabres.2012.11.012.

41. Wan Z., Song L., Hu L., et al. Helicobacter pylori infection is associated with diabetes among Chinese adults. J Diabetes Invest. 2020 Jan;11(1):199-205. doi: 10.1111/jdi.13102.

42. Hsieh M.C., Wang S. S., Hsieh Y. T., Kuo F. C., et al. Helicobacter pylori infection associated with high H b a 1c and type 2 diabetes. Eur J Clin Investig. 2013 Sep;43(9):949-56. doi: 10.1111/eci.12124.

43. Song X., Cai C., Jin Q., Chen X., et al. The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: A systematic review and meta-analysis. Helicobacter. 2021 Apr; 26(2): e12781. doi: 10.1111/hel.12781.

44. Cheng K.P., Yang Y. J., Hung H. C., et al. Helicobacter pylori eradication improves glycemic control in type 2 diabetes patients with asymptomatic active Helicobacter pylori infection. J Diabetes Investig. 2019 Jul;10(4):1092-1101. doi: 10.1111/jdi.12991.

45. Vafaeimanesh J., Parham M., Seyyedmajidi M., Bagherzadeh M. Helicobacter pylori infection and insulin resistance in diabetic and nondiabetic population. ScientificWorldJournal. 2014;2014:391250. doi: 10.1155/2014/391250.

46. Chung G.E., Heo N. J., Park M. J., Chung S. J., et al. Helicobacter pylori seropositivity in diabetic patients is associated with microalbuminuria. World J Gastroenterol. 2013 Jan 7;19(1):97-102. doi: 10.3748/wjg.v19.i1.97.

47. Moretti E., Figura N., Campagna M. S., et al. Sperm parameters and semen levels of inflammatory cytokines in Helicobacter pylori-infected men. Urology. 2015 Jul;86(1):41-6. doi: 10.1016/j.urology.2015.02.068.

48. Sze M.A., Chen Y. W., Tam S., et al. The relationship between Helicobacter pylori seropositivity and COPD. Thorax. 2015 Oct;70(10):923-9. doi: 10.1136/thoraxjnl-2015-207059.

49. Zielen S., Trischler J., Schubert R. Lipopolysaccharide challenge: immunological effects and safety in humans. Exp Rev Clin Immunol. 2015 Mar;11(3):409-18. doi: 10.1586/1744666X.2015.1012158.

50. Klok M.D., Jakobsdottir S., Drent M. L. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev. 2007 Jan;8(1):21-34. doi: 10.1111/j.1467-789X.2006.00270.x.

51. Ronveaux C.C., Tome D., Raybould H. E. Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling. J Nutr. 2015 Apr;145(4):672-80. doi: 10.3945/jn.114.206029.

52. Yang Y.F., Li Y., Liu J. H., et al. Relation of Helicobacter pylori infection to peripheral arterial stiffness and 10-year cardiovascular risk in subjects with diabetes mellitus. Diab Vasc Dis Res. 2020; 17(5):1479164120953626. doi:10.1177/1479164120953626.

53. Pyo J.H., Lee H., Choi S. C., et al. Lack of association between past Helicobacter pylori infection and diabetes: a two-cohort study. Nutrients. 2019 Aug 12;11(8):1874. doi: 10.3390/nu11081874.

54. Yang S., Xia Y. P., Luo X. Y., Chen S. L., et al. Exosomal CagA derived from Helicobacter pylori-infected gastric epithelial cells induces macrophage foam cell formation and promotes atherosclerosis. J Mol Cell Cardiol. 2019 Oct;135:40-51. doi: 10.1016/j.yjmcc.2019.07.011.

55. Shimamoto T., Yamamichi N., Gondo K., Takahashi Y., et al. The association of Helicobacter pylori infection with serum lipid profiles: An evaluation based on a combination of meta-analysis and a propensity score-based observational approach. PLoS ONE. 2020; 15: e0234433. doi: 10.1371/journal.pone.0234433.

56. Iwai N., Okuda T., Oka K., Hara T., et al. Helicobacter pylori eradication increases the serum high density lipoprotein cholesterol level in the infected patients with chronic gastritis: A single-center observational study. PLoS One. 2019 Aug 16;14(8): e0221349. doi: 10.1371/journal.pone.0221349.

57. Upala S., Sanguankeo A., Saleem S. A., Jaruvongvanich V. Effects of Helicobacter pylori eradication on insulin resistance and metabolic parameters: A systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 2017; 29:153-159. doi: 10.1097/MEG.0000000000000774.

58. Watanabe J., Hamasaki M., Kotani K. The Effect of Helicobacter pylori Eradication on Lipid Levels: A Meta-Analysis. J Clin Med. 2021;10 (5): 904. doi:10.3390/jcm10050904

59. Liu J., Wang F., Shi S. Helicobacter pylori Infection Increase the Risk of Myocardial Infarction: A Meta-Analysis of 26 Studies Involving more than 20,000 Participants. Helicobacter. 2015 Jun;20(3):176-83. doi: 10.1111/hel.12188.

60. Sun J., Rangan P., Bhat S. S., Liu L. A. Meta-Analysis of the Association between Helicobacter pylori Infection and Risk of Coronary Heart Disease from Published Prospective Studies. Helicobacter. 2016 Feb;21(1):11-23. doi: 10.1111/hel.12234.

61. Yoshikawa H., Aida K., Mori A., Muto S., et al. Involvement of Helicobacter pylori infection and impaired glucose metabolism in the increase of brachial-ankle pulse wave velocity. Helicobacter. 2007 Oct;12(5):559-66. doi: 10.1111/j.1523-5378.2007.00523.x.

62. Lee M., Baek H., Park J. S., Kim S., et al. Current Helicobacter pylori infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: A cross-sectional study. PLoS One. 2018 Mar 2;13(3): e0193646. doi: 10.1371/journal.pone.0193646.

63. Figura N., Palazzuoli A., Vaira D., Campagna M., et al. Cross-sectional study: CagA-positive Helicobacter pylori infection, acute coronary artery disease and systemic levels of B-type natriuretic peptide. J Clin Pathol. 2014 Mar;67(3):251-7. doi: 10.1136/jclinpath-2013-201743.

64. Pietroiusti A., Diomedi M., Silvestrini M., Cupini L. M., et al. Cytotoxin-associated gene-A - positive Helicobacter pylori strains are associated with atherosclerotic stroke. Circulation. 2002 Jul 30;106(5):580-4. doi: 10.1161/01.cir.0000023894.10871.2f.

65. Fang Y., Fan C., Xie H. Effect of Helicobacter pylori infection on the risk of acute coronary syndrome: a systematic review and meta-analysis. Medicine (Baltimore). 2019 Dec;98(50): e18348. doi: 10.1097/MD.0000000000018348.

66. Choi J.M., Lim S. H., Han Y. M., et al. Association between Helicobacter pylori infection and arterial stiffness: results from a large cross-sectional study. PLoS One. 2019 Aug 29;14(8): e0221643. doi: 10.1371/journal.pone.0221643.

67. Zhang L., Chen Z., Xia X., et al. Helicobacter pylori infection selectively increases the risk for carotid atherosclerosis in young males. Atherosclerosis. 2019 Dec;291:71-77. doi: 10.1016/j.atherosclerosis.2019.10.005.

68. Yang Y.F., Li Y., Liu J. H., Wang X. M., et al. Relation of Helicobacter pylori infection to peripheral arterial stiffness and 10-year cardiovascular risk in subjects with diabetes mellitus. Diab Vasc Dis Res. 2020; 17(5):1479164120953626. doi: 10.1177/1479164120953626.

69. Li N., Liu S. F., Dong K., et al. Exosome-transmitted miR-25 induced by H pylori promotes vascular endothelial cell injury by targeting KLF2. Front Cell Infect Microbiol. 2019 Oct 29;9:366. doi: 10.3389/fcimb.2019.00366.

70. Камышникова Л. А., Ефремова О. А., Гусейнли Э. Г., Gusejnli E. G. Современный обзор: Helicobacter pylori и риск развития ишемической болезни сердца. Научный результат. Медицина и фармация. 2016; 2 (3): 3-10. doi: 10.18413/2313-8955-2016-2-3-3-10.

71. Furuto Y., Kawamura M., Yamashita J, et al. Relationship Between Helicobacter pylori Infection and Arteriosclerosis. Int J Gen Med. 2021; 14:1533-1540. doi: 10.2147/IJGM.S303071.

72. Murray L.J., Bamford K. B., Kee F., et al. Infection with virulent strains of Helicobacter pylori is not associated with ischaemic heart disease: evidence from a population-based case-control study of myocardial infarction. Atherosclerosis. 2000; 149(2): 379-385. doi: 10.1016/S0021-9150(99)00325-1.

73. Slomiany B.L., Slomiany A. Induction in gastric mucosal prostaglandin and nitric oxide by Helicobacter pylori is dependent on MAPK/ERK-mediated activation of IKK-β and cPLA2: modulatory effect of ghrelin. Inflammopharmacology. 2013; 21(3): 241-251. doi: 10.1007/s10787-013-0169-5.

74. Ramji D.P., Davies T. S. Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev. 2015 Dec;26(6):673-85. doi: 10.1016/j.cytogfr.2015.04.003.

75. Pellicano R., Fagoonee S., Rizzetto M., Ponzetto A. Helicobacter pylori and coronary heart disease: which directions for future studies? Crit Rev Microbiol. 2003;29(4):351-9. doi: 10.1080/713608015.

76. Nasrat S.A.M, Nasrat A. M. An alternative approach for the rising challenge of hypertensive illness via Helicobacter pylori eradication. Cardiol Res. 2015; 6(1):221-225. doi: 10.14740/cr382e.

77. Viayvergiya R., Vadivelu R. Role of Helicobacter pylori infection in pathogenesis of atherosclerosis. World J Cardiol. 2015; 7(3):134-143. doi: 10.4330/wjc. v7.i3.134.

78. Figura N., Palazzuoli A., Vaira D., et al. Cross-sectional study: cagA-positive Helicobacter pylori infection, acute coronary artery disease and systemic levels of B-type natriuretic peptide. J Clin Pathol. 2014; 67(3): 251-257. doi: 10.1136/jclinpath-2013-201743.

79. Tamura A., Fujioka T., Nasu M. Relation of Helicobacter pylori infection to plasma vitamin B12, folic acid, and homocysteine levels in patients who underwent diagnostic coronary arteriography. Am J Gastroenterol. 2002 Apr;97(4):861-6. doi: 10.1111/j.1572-0241.2002.05601.x.

80. Kutluana U., Kilciler A. G. Is there a possible relationship between gastric intestinal metaplasia and systemic arterial stiffness? Rev Esp Enferm Dig. 2019 Jul;111(7):500-506. doi: 10.17235/reed.2019.5945/2018.